Ligand-based design, synthesis and biochemical evaluation of potent and selective inhibitors of Schistosoma mansoni dihydroorotate dehydrogenase

Autor(es)

Calil, Felipe A. ^[1] ; David, Juliana S. ^[1] ; Chiappetta, Estela R. C. ^[2] ; Fumagalli, Fernando ^[2] ; Mello, Rodrigo B. ^[2] ; Leite, Franco H. A. ^[3] ; Castilho, Marcelo S. ^[4] ; Emery, Flavio S. ^[2] ; Cristina Nonato, M. ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, Lab Cristalog Prot, BR-14040903 Ribeirao Preto, SP - Brazil

^[2] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, Lab Quim Heterocicl & Med, BR-14040903 Ribeirao Preto, SP - Brazil

^[3] Univ Estadual Feira de Santana, Lab Modelagem Mol, BR-44036900 Feira De Santana, BA - Brazil

^[4] Univ Fed Bahia, Fac Farm, Lab Bioinformat & Modelagem Mol, BR-40170115 Salvador, BA - Brazil

• Tipo de documento: Artigo Científico
• Fonte: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY; v. 167, p. 357-366, APR 1 2019.
• Citações Web of Science: 0

Resumo

Schistosomiasis ranks second only to malaria as the most common parasitic disease worldwide. 700 million people are at risk and 240 million are already infected. Praziquantel is the anthelmintic of choice but decreasing efficacy has already been documented. In this work, we exploited the inhibition of Schistosoma mansoni dihydroorotate dehydrogenase (SmDHODH) as a strategy to develop new therapeutics to fight schistosomiasis. A series of quinones (atovaquone derivatives and precursors) was evaluated regarding potency and selectivity against both SmDHODH and human DHODH. The best compound identified is 17 (2-hydroxy-3-isopentylnaphthalene-1,4-dione) with IC50 = 23 +/- 4 nM and selectivity index of 30.83. Some of the new compounds are useful pharmacological tools and represent new lead structures for further optimization. (C) 2019 Elsevier Masson SAS. All rights reserved. (AU)

• Processo FAPESP: 15/25099-5 - Reposicionamento de fármacos antimaláricos no tratamento da esquistossomose baseado na inibição seletiva da enzima diidroorotato desidrogenase
• Beneficiário: Felipe Antunes Calil
• Linha de fomento: Bolsas no Brasil - Doutorado
• Processo FAPESP: 17/21146-4 - Explorando a química heterocíclica e a epigenética para o desenvolvimento de compostos de interesse químico medicinal
• Beneficiário: Flavio da Silva Emery
• Linha de fomento: Auxílio à Pesquisa - Regular
• Processo FAPESP: 15/06588-5 - Desenvolvimento de uma biblioteca de fragmentos heterocíclicos baseada em novos núcleos heteroaromáticos
• Beneficiário: Fernando Fumagalli
• Linha de fomento: Bolsas no Brasil - Doutorado